Petros Pharmaceuticals Enters Liquidation via Assignment for Benefit of Creditors

What Happened

• Petros Pharmaceuticals, Inc. (PTPI) filed an 8-K on Sept. 30, 2026 announcing it executed a General Assignment for the Benefit of Creditors (the “Assignment” or “ABC”) under California law, assigning its assets to PT Liquidation, LLC as Assignee. The company says the Assignment constitutes a liquidation event; it has ceased substantially all business operations and “no longer has the ability to continue as a going concern.”

Key Details

• Assignment/Assignee: Assets assigned to PT Liquidation, LLC; Assignment described as a state-law liquidation event (ABC).
• Leadership changes (effective Sept. 30, 2026): Joshua N. Silverman (Executive Chairman), Bruce T. Bernstein (Director), and Wayne R. Walker (Director) resigned. Fady Boctor was terminated as President and Chief Commercial Officer. Robert Weinstein resigned as Chief Accounting Officer / Principal Financial Officer / Principal Accounting Officer effective 5:30 p.m. ET.
• Triggering event: The company reported the Assignment is a triggering event that may accelerate or increase direct financial obligations or off‑balance‑sheet arrangements (Item 2.04).
• Contact for creditors/queries: PT Liquidation, LLC, 2261 Market Street, Suite 95526, San Francisco, CA 94114.

Why It Matters

• For investors and creditors, the ABC signals formal liquidation of company assets rather than continued operations; management has largely departed and the Assignee will administer asset sales and creditor claims. The filing indicates there may be limited or no distributions, subject to the Assignee’s administration of claims. The company also included standard forward‑looking statement disclaimers and disclaimed an obligation to update those statements.